Treatment with Gallopamil: Results of Recent Research on Calcium Antagonism

ISBN-13: 9783642853784 / Angielski / Miękka / 2011 / 194 str.

F. Bender; W. Meesmann

Opis

Calcium antagonists are currently the most extensively investigated drugs for the treatment of heart disease. They are used worldwide with great success and a comparatively low incidence of adverse reactions. The most prevalent and threatening diseases in modem industrialized societies - the various forms and complications of coronary arteriosclerosis and arterial hypertension - are amenable to treatment with calcium antagonists. The pharmacological spectrum of calcium antagonists is highly specific and was supplemen ted a few years ago by gallopamil, a verapamil analogue. The experimental work reported at this symposium was concerned with effects of gallopamil on the electrophysiology of the heart, particularly in acute myocardial ischemia. New therapeutic features of myocardial hypertrophy and hypertrophic cardiomyopathy are discussed. In medical practice, gallopa mil has proved particularly useful for the treatment of angina pectoris. Studies comparing gallopamil with other calcium antagonists are described to profile the properties of the drugs in terms of their specific therapeutic value. There is still a need for more differential therapeutic trials. This first international symposium on gallopamil was attended by experts from institutions devoted to theoretical and clinical research and general practice."

Spis treści

Pharmacological aspects of calcium antagonism.- Discussion.- Comparative effects of calcium antagonists and of inotropic agents on the development of hereditary cardiomyopathy in the hamster.- Discussion.- Haemorheological effects of gallopamil in angina pectoris — A controlled study.- Effect of gallopamil on local excitability, conduction and the index of arrhythmogeniCity in the early phase of acute myocardial ischaemia.- Discussion.- Effects of gallopamil and nifedipine on ventricular arrhythmias, ventricular fibrillation, epicardial conduction delays and changes in the ventricular fibrillation threshold with time during myocardial ischaemia and reperfusion.- Discussion.- Time courses of extracellular myocardial potassium activity during acute myocardial ischaemia and the effect of gallopamil in dogs and pigs.- Discussion.- New aspects on the pathophysiology of coronary heart disease.- Discussion.- The status of calcium antagonists in the drug treatment of coronary heart disease.- Discussion.- Haemodynamic effects of gallopamil in patients with coronary heart disease and/or pulmonary hypertension.- The effect of oral gallopamil on global and regional ventricular function in patients with coronary heart disease.- Discussion.- Treatment of chronic stable angina pectoris with gallopamil.- Discussion.- Time course of the response to gallopamil in the steady State in the exercise ECG of patients with coronary heart disease.- Discussion.- Effects of gallopamil in patients with severe coronary heart disease: Investigations by radionuclide ventriculography.- Discussion.- Effects of intravenous and oral treatment with calcium antagonists on myocardial microperfusion.- Incidence and importance of silent myocardial ischaemia — treatment with gallopamil.- Discussion.- Anti-anginal effect of gallopamil versus nifedipine.- Discussion.- Clinical and electrocardiographic effects of gallopamil and nifedipine in patients with coronary heart disease receiving basic treatment with ISDN.- Discussion.- Assessment of gallopamil (D600) in patients with chronic stable angina pectoris Results of a placebo-controlled single-blind study.- Discussion.- Gallopamil and six other calcium antagonists in stable angina pectoris and a within-patient comparison of gallopamil with diltiazem.- Discussion.